ICU Medical

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICU Medical reports mixed Q4 results, eyes mid-single-digit growth

ICU Medical's Q4 2022 performance showcased mixed results, with revenue declines in legacy ICU Medical offset by improvements in Infusion Systems and Vital Care at Smiths Medical.
The company provided 2023 guidance with expectations of mid-single-digit revenue growth, improved gross margin, and a focus on addressing inflationary pressures and controlling costs.
Challenges included revenue shortfalls, supply interruptions, and concerns about operating margins, while opportunities exist in addressing FX impacts, regaining lost revenues, and enhancing operational efficiency.
Overall, ICU Medical remains focused on driving business performance, maintaining customer attention, and creating value through strategic realignment and operational synergies.

ICU Medical reports robust Q1 performance amidst segment-specific challenges

ICU Medical delivered a strong Q1 performance with revenue growth across segments and improved profitability metrics, showcasing operational strength.
While facing challenges in the Vascular Access segment, the company aims for growth in Consumables and maintains a positive outlook for the year.
Opportunities for revenue growth and financial optimization through operational efficiency improvements and strategic initiatives highlight potential avenues for future success.

ICU Medical reports Q2 earnings, adjusts guidance, focuses on stability

ICU Medical's Q2 2023 earnings call highlighted financial results, ongoing integration efforts, and a focus on stability and growth. The company remains confident in recapturing market share over time and aims for a full-year gross margin target of 37%.

ICU Medical reports Q3 results, focuses on growth and efficiency

ICU Medical reported mixed Q3 2023 financial results with adjusted revenues of $547 million and a 7% decrease in GAAP revenue year-over-year.
The company demonstrated strengths in maintaining a 36% adjusted gross margin, positive free cash flow, and a focus on operational efficiency.
Challenges included revenue declines in certain business segments and the need to address analyst concerns regarding margins and revenue growth.
Opportunities lie in product innovation, cash flow optimization, and a commitment to driving revenue growth and operational efficiency for long-term success.

ICU Medical reports solid Q4 results, focuses on margin improvement

ICU Medical's Q4 performance showed revenue growth and strong cash flow, with a focus on margin improvement and revenue growth in 2024. Challenges include competitive pump market dynamics and inventory drawdown impact on margins. The company aims to capitalize on opportunities for inventory reductions and margin enhancement.

ICU Medical reports steady Q1 growth, focuses on operational efficiency

ICU Medical's Q1 2024 performance showed steady revenue growth and improved margins driven by operational efficiencies. While facing challenges in certain segments, the company's focus on quality remediation and positive free cash flow generation bode well for future stability and growth.
Strategic opportunities exist in optimizing the Vital Care segment and leveraging strengths in the Consumables business. Continued emphasis on operational efficiency and product mix could position ICU Medical for sustained success in the healthcare market.

ICU Medical posts robust Q2 results, raises full-year guidance

ICU Medical delivered a strong Q2 performance with revenue growth and margin improvement.
The company's financial health is solid, with raised full-year guidance indicating confidence in future prospects.
Challenges include managing operating expenses and sustaining growth in a competitive market.
Strategic focus on innovation and efficiency presents opportunities for continued expansion and success.

ICU Medical posts robust Q3 results, raises guidance amid JV

ICU Medical's Q3 performance reflects strength in key segments and operational efficiency.
Challenges lie in the impact of the JV on financials and liquidity concerns from outstanding AR purchases.
Opportunities abound with raised guidance, strategic JV, and positive operational updates.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICU Medical, Inc. develops, manufactures, and sells innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

ICU Medical Inc. (NASDAQ:ICUI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Mills - ICR Vivek Jain - Chief Executive Officer and Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Brett Fishbin - KeyBanc Eric Fleming - Raymond James Larry Solow - CJS Securities Kristen Stewart - CL King Mike Matson - Needham and Company Michael Toomey - Jefferies Operator Good day, everyone, and welcome to today's ICU Medical Inc.'s Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

ICU Medical Inc. (ICUI) Q3 2024 Earnings Call Transcript

ICU Medical (ICUI) came out with quarterly earnings of $1.59 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.57 per share a year ago.

ICU Medical (ICUI) Tops Q3 Earnings and Revenue Estimates

The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. Joint venture becomes part of a global manufacturing network with scale and redundancy Intends to add long-term supply resiliency and accelerate IV solutions new product development in North America Combines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distribution ICU Medical to provide commercial services to the joint venture Expected to become operationally effective in early Q2 2025 Full presentation available for view here SAN CLEMENTE, Calif.

ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America

SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in Rancho Palos Verdes, California, November 11-14, 2024. ICU Medical's presentation will be on Wednesday, November 13, 2024 at 4:15 p.m. PT (7:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, November 13, 2024.

ICU Medical to Participate at the UBS Global Healthcare Conference

ICU Medical (ICUI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICU Medical (ICUI) Expected to Beat Earnings Estimates: Should You Buy?

SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call.

ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call

ICU Medical (ICUI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will ICU Medical (ICUI) Beat Estimates Again in Its Next Earnings Report?

ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.

ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall

ICU Medical (ICUI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ICU Medical, Inc. (ICUI) Hits Fresh High: Is There Still Room to Run?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is ICU Medical (ICUI) Stock Undervalued Right Now?

SAN CLEMENTE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September:

ICU Medical to Participate in Upcoming Investor Conferences

ICU Medical Inc (NASDAQ:ICUI ) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants John Mills - Managing Partner Vivek Jain - CEO & Chairman of the Board Brian Bonnell - CFO & Treasurer Conference Call Participants Larry Solow - CJS Securities Kristen Stewart - CL King Brett Fishbin - KeyBanc Capital Markets Mike Matson - Needham & Company Jayson Bedford - Raymond James Operator Good afternoon, ladies and gentlemen, and welcome to the ICU Medical Inc Second Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

ICU Medical Inc (ICUI) Q2 2024 Earnings Call Transcript

ICU Medical (ICUI) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $1.88 per share a year ago.

ICU Medical (ICUI) Surpasses Q2 Earnings and Revenue Estimates

ICU Medical, Inc. (NASDAQ:ICUI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants John Mills - Managing Partner at ICR Vivek Jain - Chief Executive Officer & Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Brett Fishbin - KeyBanc Kristen Stewart - CL King Larry Solow - CJS Securities Operator Good afternoon, ladies and gentlemen and welcome to the ICU Medical Incorporated. First Quarter 2024 Earnings Conference Call.

ICU Medical, Inc. (ICUI) Q1 2024 Earnings Call Transcript

ICU Medical (ICUI) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $1.74 per share a year ago.

ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates

SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024.

ICU Medical Announces First Quarter 2024 Results

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call.

ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call

SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024. ICU Medical's presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024.

ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum

SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024. ICU Medical's presentation will be on Monday, March 4, 2024 at 4:30 a.m. PT (7:30 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, March 4, 2024.

ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference

ICU Medical, Inc. (ICUI) Q4 2023 Earnings Call Transcript

ICU Medical (ICUI) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.60 per share a year ago.

ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates

SAN CLEMENTE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023.

ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance

Ardmore Shipping

The recent surge in analyst coverage for stocks such as ICU Medical (ICUI) and Ardmore Shipping (ASC) indicates the potential for significant price appreciation in the near term.

2 Stocks in Focus as New Analysts Initiate Coverage

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call.

News for ICU Medical Stock (ICUI)